HRT Financial’s Tarsus Pharmaceuticals TARS Stock Holding History

HRT Financial’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,774	Closed	-$2.03M	–	4700
2025 Q4	$2.03M	Buy	+24,774	New	+$1.85M	0.01%	1295

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

HRT Financial's TARS Position: Q1 2026 in Review

HRT Financial sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 24,774 shares — an estimated $2.03M sold.

HRT Financial first reported a position in TARS in Q4 2025 and held it in 1 quarter. The position peaked at $2.03M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

HRT Financial reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 24,774 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $2.03M.
HRT Financial first reported a position in Tarsus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
HRT Financial's Tarsus Pharmaceuticals position peaked at $2.03M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.